Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01385059 · ClinicalTrials.gov registry record · Phase 2
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01385059 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 11 participants.
The verdict
NCT01385059, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well axitinib works in treating patients with high-risk prostate cancer before undergoing surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving axitinib before surgery may make the tumor smaller and reduce the amount of normal cells that have to be removed
Interventions
- OTHER laboratory biomarker analysis
- DRUG axitinib
- PROCEDURE therapeutic conventional surgery
- OTHER enzyme-linked immunosorbent assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-10-28 |
| Est. Completion | 2013-10-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01385059
The ClinicalTrials.gov registry entry for NCT01385059 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01385059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01385059 about?
NCT01385059 is a clinical study titled "Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer". This randomized phase II trial studies how well axitinib works in treating patients with high-risk prostate cancer before undergoing surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving axitinib before surgery may make the tumor smaller ...
What is the current status of trial NCT01385059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2011-10-28. Estimated completion is 2013-10-09.
What interventions are being tested in trial NCT01385059?
The interventions under investigation include: laboratory biomarker analysis (OTHER), axitinib (DRUG), therapeutic conventional surgery (PROCEDURE), enzyme-linked immunosorbent assay (OTHER).
Who is sponsoring clinical trial NCT01385059?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.